

# **Beyond initial GWAS analysis: two-stage designs, family data, imputation, meta-analysis**

Gonçalo Abecasis

University of Michigan School of  
Public Health


# Genomewide Association Studies

- Survey 100,000 – 1,000,000 SNPs in a large set of cases and controls
- Comprehensively survey the genome for common variants of relatively small effect
- Have rapidly increased the catalog of genetic loci implicated in common disorders
  - For example, there are now ~20 loci implicated in type 2 diabetes
- The results are quite a contrast to those of earlier genetic association studies that focused on small numbers of genes and polymorphisms
- Still, much of the genetic variance of these traits remains unexplained.

# Collaborative Association Study of Psoriasis:


## Example of a Successful GWAS

- Examined ~1,500 cases / ~1,500 controls at ~500,000 SNPs
- Examined promising SNPs in extra ~5,000 cases / ~5,000 controls
- Outcome: 7 regions of confirmed association with psoriasis




Hits colored in green have  $p < 5 \times 10^{-8}$  when evidence from follow-up and original scan is combined

# HLA-C




Top psoriasis associated SNPs in **strong linkage disequilibrium with HLA-Cw6**.  
 Evidence for psoriasis associated SNPs that are far from HLA-Cw6.

# IL23R




Previously identified locus, psoriasis associated SNPs also **associated with Crohn's**.

# IL12B




Previously identified locus, psoriasis associated SNPs **associated with Crohn's**.

# IL23A




New locus, psoriasis associated SNPs **not associated** with Crohn's.

# TNFAIP3




New locus; other SNPs in the locus are associated with lupus and rheumatoid arthritis.

# TNIP1



New locus; note potential evidence for independently associated alleles.

# IL4/IL13



New locus; IL4 and IL13 are excellent functional candidates.

# Psoriasis GWAS: Summary of Replicated Loci


SNP	Alleles	Discovery samples (1,359 cases, 1,400 controls)				Follow-up samples (5,048 cases, 5,051 controls)				Combined <i>P</i> value <sup>d</sup>	Notable nearby genes (relative position) <sup>c</sup>	
		Frequency <sup>a</sup>		Frequency		OR (meta)	<i>P</i> value <sup>b</sup> (meta)					
		Case	Control	Case	Control		Combined <i>P</i> value <sup>d</sup>	Notable nearby genes (relative position) <sup>c</sup>				
rs12191877	T/C	0.313	0.141	2.79	$4 \times 10^{-53}$	0.301	0.147	2.64	$<10^{-100}$	$<10^{-100}$	<i>HLA-C</i> (-13 kb)	
rs2082412	G/A	0.856	0.792	1.56	$5 \times 10^{-10}$	0.848	0.798	1.44	$3 \times 10^{-20}$	$2 \times 10^{-28}$	<i>IL12B</i> (+24 kb)	
rs17728338	A/G	0.093	0.056	1.72	$2 \times 10^{-7}$	0.087	0.054	1.59	$6 \times 10^{-15}$	$1 \times 10^{-20}$	<i>TNIP1</i> (-12 kb)	
rs20541	G/A	0.832	0.783	1.37	$6 \times 10^{-6}$	0.827	0.790	1.27	$1 \times 10^{-10}$	$5 \times 10^{-15}$	<i>IL13</i> (nonsynonymous)	
rs610604	G/T	0.374	0.318	1.28	$1 \times 10^{-5}$	0.360	0.320	1.19	$7 \times 10^{-8}$	$9 \times 10^{-12}$	<i>TNFAIP3</i> (intronic)	
rs2066808 <sup>d</sup>	A/G	0.958	0.931	1.68	$2 \times 10^{-5}$	0.947	0.932	1.34	$5 \times 10^{-6}$	$1 \times 10^{-9}$	<i>IL23A</i> (+3.7 kb) <i>STAT2</i> (intronic)	
rs2201841	G/A	0.350	0.286	1.35	$3 \times 10^{-7}$	0.325	0.295	1.13	$4 \times 10^{-4}$	$3 \times 10^{-8}$	<i>IL23R</i> (intronic)	

# Multiple hits within a pathway...

- Three of the top replicated hits are for:
  - IL23R (IL-23 receptor)  $3 \times 10^{-8}$
  - IL23A (IL-23 subunit)  $9 \times 10^{-10}$
  - IL12B (IL-23/IL-12 subunit)  $1 \times 10^{-28}$
- Two other replicated hits at:
  - TNFAIP3 (TNF $\alpha$ -inducible protein 3)  $9 \times 10^{-12}$
  - TNIP1 (TNFAIP3 interacting protein 1)  $1 \times 10^{-20}$
- Evidence for epistasis among these SNPs?
  - None.

# Additional Phenotype Information

- Evaluation of gene expression for ~50,000 transcripts
  - Affymetrix U133 Plus 2.0 Arrays
- Skin biopsies
  - 40 control biopsies (buttock)
  - 40 biopsies of unaffected skin from cases (buttock)
  - 40 biopsies of affected skin from cases (plaque)
- Early assessment of the impact of any associated variants we identify
  - Comparison of control and unaffected skin biopsies particularly interesting




Four of the the functional candidates show increased expression in psoriatic skin.

# Other Hits Supported by Our Study


- Support for association with deletion in late cornified envelope region (LCE) identified by Xavier Estivill ( $p \sim 0.001$ )
- Support for association with ZNF313, a potential regulator of T-cell activation ( $p \sim 10^{-4}$ )
- Some support for association with IBD5 region

# One- and Two-Stage GWA Designs

One-Stage Design




Two-Stage Design




# Analyzing Two Stage Designs

**Replication-based analysis**



**Joint analysis**



# Joint Analysis: Statistics

- The standard test statistic for comparing allele frequencies could be expressed as:

$$z = \frac{\hat{p}_{case} - \hat{p}_{control}}{\sqrt{(\hat{p}_{case}(1 - \hat{p}_{case}) + \hat{p}_{control}(1 - \hat{p}_{control})) / 2N}}$$


- Based on  $z_{stage1}$  and  $z_{stage2}$  the joint statistic is:

$$z_{joint} = z_{stage1} \sqrt{\frac{N_1}{N_1 + N_2}} + z_{stage2} \sqrt{\frac{N_2}{N_1 + N_2}}$$

- Note that using  $z_{joint}$  will require a more stringent significance threshold than using  $z_2$

## Two Stage Design Power

50% of samples typed in phase 1  
1% of markers followed up in phase 2




M = 300,000 markers

N = 1000 cases, 1000 controls


GRR = 1.4 (multiplicative model)

Prevalence = .10

# Replication or Joint Analysis: Proportion of Markers Followed Up



# Replication or Joint Analysis: Proportion of Samples Followed Up



# Multistage Designs

- Genotyping costs can be substantially reduced when staged approach is used
- Typically, cost can be reduced by 40-60% depending on ratio of genotyping costs between stages 1 and 2
- [www.sph.umich.edu/csg/abecasis/CaTS](http://www.sph.umich.edu/csg/abecasis/CaTS)
- //workshop/goncaloa/2009/CaTS-setup.exe
- (f:/goncaloa/2009/merlin-examples/)

# Beyond the Initial Analysis

- **Things that we already know will work ...**
  1. **Imputation of genome scan genotypes in relatives**
  2. **Imputation of HapMap genotypes in everyone**
  3. **Meta-analysis of genome wide scans**
  4. **Contrasting results for scans targeting related traits**
- **Things that might work ...**
  1. Screening for rare variants
  2. Screening for interactions
  3. Focusing on the “right” pathways
  4. Studying copy number polymorphisms
- **Things for molecular biologists to do ...**
  1. Many new targets to investigate


# In Silico Genotyping For Family Samples

- Family members share large segments of chromosomes
- If we genotype many related individuals, we will effectively be genotyping a few chromosomes many times
- Propagate genotypes obtained in genome wide association study to related individuals
- Propagation can be based just on genetic relationships ...
- ... but will work better if we first identify shared chromosomal regions in each family using a subset of markers

Burdick et al, *Nat Genet*, 2006  
Chen and Abecasis, *AJHG*, 2007


# Genotype Inference

## Part 1 – Observed Genotype Data




# Genotype Inference

## Part 2 – Inferring Allele Sharing



# Genotype Inference

## Part 3 – Imputing Missing Genotypes



# Formal Approach

- Consider full set of observed genotypes  $G$
- Evaluate pedigree likelihood  $L$  for each possible value of each missing genotype  $g_{ij}$
- Posterior probability for each missing genotype

$$P(g_{ij} = x \mid G) = \frac{L(G, g_{ij} = x)}{L(G)}$$

- Optimally, downstream analyses should use probabilistic genotype assignments rather than a single most likely genotype

# Standard Linear Model for Genetic Association

- Model association using a model such as:

$$E(y_i) = \mu + \beta_g g + \beta_c c + \dots$$

- $y_i$  is the phenotype for individual  $i$
- $g_i$  is the genotype for individual  $i$ 
  - Simplest coding is to set  $g_i$  = number of copies of allele ‘1’
- $c_i$  is a covariate for individual  $i$ 
  - Covariates could be estimated ancestry, environmental factors...
- $\beta$  coefficients are estimated covariate, genotype effects
- Model is fitted in variance component framework

# Model With Inferred Genotypes

- Replace genotype score  $g$  with its expected value:

$$E(y_i) = \mu + \beta_g \bar{g} + \beta_c c + \dots$$

- Where

$$\bar{g}_i = 2P(g_i = 2 | G) + P(g_i = 1 | G)$$

- Association test implemented as score test or as likelihood ratio test
  - Variance component framework to allow for relatedness
- Alternatives would be to
  - (a) impute genotypes with large posterior probabilities; or
  - (b) integrate joint distribution of unobserved genotypes in family

# Score Test for Association

- A standard variance component analysis would work ...
- ... but might be rather slow on a genomewide scale
- We can approximate the result that would be obtained from maximum likelihood estimation using a rapid score test:


$$T^{\text{SCORE}} = \frac{\left\{ \sum_i [\bar{g}_i - E(\bar{g}_i)]' [\Omega_i^{(\text{base})}]^{-1} [\mathbf{y}_i - E(y_i)^{(\text{base})}] \right\}^2}{\sum_i [\bar{g}_i - E(\bar{g}_i)]' [\Omega_i^{(\text{base})}]^{-1} [\bar{g}_i - E(\bar{g}_i)]}$$

- Similar approaches could actually be used for unrelated individuals, provided we can model an appropriate variance-covariance matrix

# Quantitative Trait GWAS in Sardinia

- 6,148 Sardinians from 4 towns in Ogliastra
- Measured 98 aging related quantitative traits
- Genotyping:
  - 10,000 SNPs measured in ~4,500 individuals
  - 500,000 SNPs measured in ~1,400 individuals
- So far, we have confidently identified genes involved in traits as disparate as obesity and height, the regulation of cholesterol, uric acid and glucose levels, among others

# FTO and Obesity Related Traits



Scuteri et al, PLoS Genetics, 2007

# MERLIN Exercise

## Imputation within Families, Association

- We will look at the MERLIN tutorial on association analysis  
[http://www.sph.umich.edu/csg/abecasis/Merlin/tour//workshop/goncaloa/2009/merlin-examples/\(f:/goncaloa/2009/merlin-examples/\)](http://www.sph.umich.edu/csg/abecasis/Merlin/tour//workshop/goncaloa/2009/merlin-examples/(f:/goncaloa/2009/merlin-examples/))
- Merlin will fill in missing genotypes based on information on relatives
- Merlin implements two flavors of association testing:
  - The **--assoc** option implements maximum likelihood testing
  - The **--fastassoc** option implements the score test approach

# Relatedness in The Context of GWAS

- When analyzing family samples ...
- FOR INDIVIDUALS WITH KNOWN RELATIONSHIPS
  - Impute genotypes in relatives, who may be completely untyped
  - Imputation works through long shared stretches of chromosome
- But the majority of GWAS that use “unrelated” individuals...

# Relatedness in The Context of GWAS

- When analyzing family samples ...
- FOR INDIVIDUALS WITH KNOWN RELATIONSHIPS
  - Impute genotypes in relatives, who may be completely untyped
  - Imputation works through long shared stretches of chromosome
- But the majority of GWAS that use “unrelated” individuals...
- FOR INDIVIDUALS WITH UNKNOWN RELATIONSHIPS
  - Impute observed genotypes in relatives
  - Imputation works through short shared stretches of chromosome

# Observed Genotypes

## Observed Genotypes

..... A .. . . . . . . . A .. . . . . A .. . . .  
..... G .. . . . . . . . C .. . . . . A .. . . .

Study  
Sample

## Reference Haplotypes

C G A G A T C T C C T T C T T C T G T G C  
C G A G A T C T C C C G A C C T C A T G G  
C C A A G G C T C T T T T C T T C T G T G C  
C G A A G G C T C T T T T C T T C T G T G C  
C G A G A C T C T C C C G A C C T T A T G C  
T G G G A T C T C C C G A C C T C A T G G  
C G A G A T C T C C C G A C C T T G T G C  
C G A G A C T C T T T T C T T T T G T A C  
C G A G A C T C T C C C G A C C T C G T G C  
C G A A G G C T C T T T T C T T C T G T G C

HapMap

# Identify Match Among Reference

## Observed Genotypes

..... A .. . . . . . . . A .. . . . . A .. . . .  
..... G .. . . . . . . . C .. . . . . A .. . . .

## Reference Haplotypes

C	G	A	G	A	T	C	T	C	C	T	T	C	T	T	C	T	G	T	G	C
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G
C	C	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	T	A	T	G	C
T	G	G	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	T	G	T	G	C
C	G	A	G	A	C	T	C	T	T	T	T	C	T	T	T	T	G	T	A	C
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	C	G	T	G	C
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C

# Phase Chromosome, Impute Missing Genotypes

## Observed Genotypes

c	g	a	g	A	t	c	t	c	c	c	g	A	c	c	t	c	A	t	g	g
c	g	a	a	G	c	t	c	t	t	t	C	t	t	t	c	A	t	g	g	

## Reference Haplotypes

C	G	A	G	A	T	C	T	C	C	T	T	C	T	T	C	T	G	T	G	C	
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G	
C	C	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C	
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C	
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	T	A	T	G	C	
T	G	G	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G	
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	T	G	T	G	C	
C	G	A	G	A	C	T	C	T	T	T	T	C	T	T	T	T	G	T	A	C	
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	C	G	T	G	C	
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	T	C	T	G	T	G	C


# Implementation

- Markov model is used to model each haplotype, conditional on all others
- Gibbs sampler is used to estimate parameters and update haplotypes
  - Each individual is updated conditional on all others
  - In parallel to updating haplotypes, estimate “error rates” and “crossover” probabilities
- In theory, this should be very close to the Li and Stephens (2003) model

# Does Imputation Really Work? Results from One Recent Assessment


- Use 438,670 SNPs to impute 2.5M SNPs in GAIN psoriasis scan
  - Nair et al, *Nature Genetics*, in press
- Re-genotyped ~906,600 SNPs in 90 samples using the Affymetrix 6.0 chip.
- Discrepancy rate of 1.80% per genotype (0.91% per allele).
  - 57,747,244 imputed genotypes compared with Affymetrix calls
  - 661,881 non-Perlegen SNPs present in the Affymetrix 6.0
- Average  $r^2$  between imputed calls and Affymetrix calls was 0.93.
  - $r^2$  exceeded 0.80 for >90% of SNPs.

## GCKR "In Silico" Fine-Mapping Using Imputation




**Association between triglycerides and GCKR**  
Sekar Kathiresan, DGI, see poster 32

## GCKR Genotyping Fine-Mapping



**Association between triglycerides and GCKR**  
Sekar Kathiresan, DGI, see poster 32

## Sardinia G6PD Activity Example ...




After imputing HapMap SNPs a region on chromosome 1 becomes top hit after G6PD and HBB

The new hit is upstream of 6PGD

6-phosphogluconate dehydrogenase is an enzyme that is known to metabolize some of the same substrates as G6PD

# LDLR and LDL example




# Impact of HapMap Imputation on Power

<b>Power</b>			
<b>Disease</b>	<b>SNP MAF</b>	<b>tagSNPs</b>	<b>Imputation</b>
	2.5%	24.4%	56.2%
	5%	55.8%	73.8%
	10%	77.4%	87.2%
	20%	85.6%	92.0%
	50%	93.0%	96.0%

Power for Simulated Case Control Studies.  
Simulations Ensure Equal Power for Directly Genotype SNPs.

Simulated studies used a tag SNP panel that captures  
80% of common variants with pairwise  $r^2 > 0.80$ .


For eQTL Mapping, Imputation Increases  
Number of *cis* eQTL by ~10%



# Combining Genomewide Studies: Cholesterol Levels Example


- HDL-Cholesterol, LDL-Cholesterol and Triglycerides
  - Strongly associated with risk of coronary artery disease
  - Important non-genetic factors include diet, statins, age
  - Several previously identified genes
  - Heritability 30-40%
- Our experiment
  - Examine 8,816 individuals from 3 genomewide scans
  - Scans used different marker platforms, combined with imputation
  - Individually, SardiNIA, FUSION and DGI scans had 1-3 hits
  - Confirm findings in >11,500 additional individuals
- Identified a total of 18 loci associated with cholesterol at  $p < 5 \times 10^{-8}$

# What do we learn from meta-analysis? Combined Lipid Scan Results




Willer et al, *Nat Genet*, 2008

# New HDL Locus




Willer et al, *Nat Genet*, 2008

# New HDL Signal For An Old Locus ...



What happens when we contrast  
results with related traits?

# New LDL Locus, Previously Associated with CAD




# Comparison with Related Traits: Coronary Artery Disease and LDL-C Alleles

Gene	LDL-C p-value	Frequency CAD cases	Frequency CAD ctrls	CAD p-value	OR
<i>APOE/C1/C4</i>	$3.0 \times 10^{-43}$	.209	.184	$1.0 \times 10^{-4}$	<b>1.17 (1.08-1.28)</b>
<i>APOE/C1/C4</i>	$1.2 \times 10^{-9}$	.339	.319	.0068	<b>1.10 (1.02-1.18)</b>
<i>SORT1</i>	$6.1 \times 10^{-33}$	.808	.778	$1.3 \times 10^{-5}$	<b>1.20 (1.10-1.31)</b>
<i>LDLR</i>	$4.2 \times 10^{-26}$	.902	.890	$6.7 \times 10^{-4}$	<b>1.29 (1.10-1.52)</b>
<i>APOB</i>	$5.6 \times 10^{-22}$	.830	.824	.18	<b>1.04 (0.95-1.14)</b>
<i>APOB</i>	$8.3 \times 10^{-12}$	.353	.332	.0042	<b>1.10 (1.03-1.18)</b>
<i>APOB</i>	$3.1 \times 10^{-9}$	.536	.520	.028	<b>1.07 (1.00-1.14)</b>
<i>PCSK9</i>	$3.5 \times 10^{-11}$	.825	.807	.0042	<b>1.13 (1.03-1.23)</b>
<i>NCAN/CILP2</i>	$2.7 \times 10^{-9}$	.922	.915	.055	<b>1.11 (0.98-1.26)</b>
<i>B3GALT4</i>	$5.1 \times 10^{-8}$	.399	.385	.039	<b>1.07 (0.99-1.14)</b>
<i>B4GALT4</i>	$1.0 \times 10^{-6}$	.874	.865	.051	<b>1.09 (0.98-1.20)</b>


Data from WTCCC; Willer et al, *Nature Genetics*, 2008

# MTNR1B influences glucose levels in non-diabetics and is a new T2D locus

**Association with glucose,**  
36,000 non-diabetics




**Association with diabetes,**  
18,000 cases vs. 64,000 controls




Prokopenko et al, *Nature Genetics*, 2009

# Does Imputation Work Across Populations?

- Conrad et al. (2006) dataset
- 52 regions, each ~330 kb
- Human Genome Diversity Panel
  - ~927 individuals, 52 populations
- 1864 SNPs
  - Grid of 872 SNPs used as tags
  - Predicted genotypes for the other 992 SNPs
  - Compared predictions to actual genotypes



## Percentage of Alleles Imputed Incorrectly




(Evaluation Using ~1 SNP per 10kb in 52 x 300kb regions For Imputation)

# Beyond the Initial Analysis

- Things that we already know will work ...
  1. Imputation of genome scan genotypes in relatives
  2. Imputation of HapMap genotypes in everyone
  3. Meta-analysis of genome wide scans
  4. Contrasting results for scans targeting related traits
- Things that might work ...
  1. Screening for rare variants
  2. Screening for interactions
  3. Focusing on the “right” pathways
  4. Studying copy number polymorphisms
- Things for molecular biologists to do ...
  1. Many new targets to investigate


Will GWAS Loci Harbor  
Additional Variants?

# Combined Lipid Scan Results




Willer et al, *Nat Genet*, 2008

# Combined Lipid Scan Results



Willer et al, *Nat Genet*, 2008

# Combined Lipid Scan Results




Willer et al, *Nat Genet*, 2008

# What about interactions?

Typical Story Parallels Our Psoriasis GWAS:  
No evidence for interactions.


# Unusual Story: BCL11A and Fetal Hemoglobin Levels



- Mapped association of fetal hemoglobin levels in adults and BCL11A variants
- BCL11A variants “rescue” thalassemia phenotype in  $\beta$ -globin null homozygotes
- Uda et al, PNAS, 2008

Focusing on the right pathways...

# Genes impacting BMI act in the brain?




Seven of eight confirmed BMI loci show strongest expression in the brain...

Willer et al, *Nature Genetics*, 2009


How important is copy number  
variation?

# NEGR1 – BMI Association




Willer et al, *Nature Genetics*, 2009

# NEGR1 – BMI Association




Willer et al, *Nature Genetics*, 2009

# Associated Haplotype Carries Deletion



Willer et al, *Nature Genetics*, 2009

# How will we do with larger reference panels? Improve Imputation and Power in all GWAS



Increasing reference panels from 60 (HapMap) to 500 individuals (1000 genomes?)  
should decrease imputation error in GWAS from ~1.4% to ~0.4%.

## **Genome-wide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways**

Rajan P. Nair<sup>1\*</sup>, Kristina Callis Duffin<sup>2\*</sup>, Cindy Helms<sup>3\*</sup>, Jun Ding<sup>4\*</sup>, Philip E. Stuart<sup>1</sup>, David Goldgar<sup>2</sup>, Johann E. Gudjonsson<sup>1</sup>, Yun Li<sup>4</sup>, Trilokraj Tejasvi<sup>1</sup>, Binjian Feng<sup>2</sup>, Andreas Ruether<sup>5</sup>, Michael Weichenthal<sup>6</sup>, Dafna Gladman<sup>7</sup>, Proton Rahman<sup>8</sup>, Steven J. Schrodi<sup>9</sup>, Sampath Prahalad<sup>10</sup>, Stephen L Guthery<sup>10</sup>, Judith Fischer<sup>11</sup>, Wilson Liao<sup>12</sup>, Pui Kwok<sup>12</sup>, Alan Menter<sup>13</sup>, G. Mark Lathrop<sup>11</sup>, C. Wise<sup>14</sup>, Ann B. Begovich<sup>9</sup>, John J. Voorhees<sup>1</sup>, James T. Elder<sup>1,15#</sup>, Gerald G. Krueger<sup>2#</sup>, Anne M. Bowcock<sup>3#</sup>, Gonçalo R. Abecasis<sup>4#</sup> for the Collaborative Association Study of Psoriasis<sup>16</sup>

- University of Utah
  - Gerald Krueger
  - Kristina Callis
  - David Goldgar
- Washington University
  - Anne Bowcock
  - Alan Menter
  - Cindy Helms
- University of Michigan
  - JT Elder
  - Rajan Nair
  - Phil Stuart
  - Johann Gudjonsson
  - John Voorhees
  - Gonçalo Abecasis
  - Yun Li
  - Jun Ding

## **Variants in the melatonin receptor 1B gene (*MTNR1B*) influence fasting glucose levels**

Inga Prokopenko<sup>1,2\*</sup>, Claudia Langenberg<sup>3\*</sup>, Jose C. Florez<sup>4-6\*</sup>, Richa Saxena<sup>4,7\*</sup>, Nicole Soranzo<sup>8,9\*</sup>, Gudmar Thorleifsson<sup>10</sup>, Ruth J.F. Loos<sup>3</sup>, Alisa K. Manning<sup>11</sup>, Anne U. Jackson<sup>12</sup>, Yurii Aulchenko<sup>13</sup>, Simon C. Potter<sup>8</sup>, Michael R. Erdos<sup>14</sup>, Serena Sanna<sup>15</sup>, Jouke-Jan Hottenga<sup>16</sup>, Eleanor Wheeler<sup>8</sup>, Marika Kaakinen<sup>17</sup>, Valeriya Lyssenko<sup>18</sup>, Wei-Min Chen<sup>19,20</sup>, Kourosh Ahmadi<sup>9</sup>, Jacques S. Beckmann<sup>21,22</sup>, Richard N. Bergman<sup>23</sup>, Murielle Bochud<sup>24</sup>, Lori L. Bonnycastle<sup>14</sup>, Thomas A. Buchanan<sup>25</sup>, Antonio Cao<sup>15</sup>, Alessandra Cervino<sup>9</sup>, Lachlan Coin<sup>26</sup>, Francis S. Collins<sup>14</sup>, Laura Crisponi<sup>15</sup>, Eco JC de Geus<sup>16</sup>, Abbas Dehghan<sup>13</sup>, Panos Deloukas<sup>8</sup>, Alex S F Doney<sup>27</sup>, Paul Elliott<sup>26</sup>, Nelson Freimer<sup>28</sup>, Vesela Gateva<sup>12</sup>, Christian Herder<sup>29</sup>, Albert Hofman<sup>13</sup>, Thomas E. Hughes<sup>30</sup>, Sarah Hunt<sup>8</sup>, Thomas Illig<sup>31</sup>, Michael Inouye<sup>8</sup>, Bo Isomaa<sup>32</sup>, Toby Johnson<sup>21,24,33</sup>, Augustine Kong<sup>10</sup>, Maria Krestyaninova<sup>34</sup>, Johanna Kuusisto<sup>35</sup>, Markku Laakso<sup>35</sup>, Noha Lim<sup>36</sup>, Ulf Lindblad<sup>37,38</sup>, Cecilia M. Lindgren<sup>2</sup>, Owen T. McCann<sup>8</sup>, Karen L. Mohlke<sup>39</sup>, Andrew D Morris<sup>27</sup>, Silvia Naitza<sup>15</sup>, Marco Orrù<sup>15</sup>, Colin N A Palmer<sup>40</sup>, Anneli Pouta<sup>41,42</sup>, Joshua Randall<sup>2</sup>, Wolfgang Rathmann<sup>43</sup>, Jouko Saramies<sup>44</sup>, Paul Scheet<sup>12</sup>, Laura J. Scott<sup>12</sup>, Angelo Scuteri<sup>14,45</sup>, Stephen Sharp<sup>3</sup>, Eric Sijbrands<sup>46</sup>, Jan H. Smit<sup>16</sup>, Kijoung Song<sup>36</sup>, Valgerdur Steinthorsdottir<sup>10</sup>, Heather M. Stringham<sup>12</sup>, Tiinamaija Tuomi<sup>47</sup>, Jaakko Tuomilehto<sup>48,49</sup>, André G. Uitterlinden<sup>46</sup>, Benjamin F. Voight<sup>4,7</sup>, Dawn Waterworth<sup>36</sup>, H.-Erich Wichmann<sup>31,50</sup>, Gonnieke Willemsen<sup>16</sup>, Jacqueline CM Witteman<sup>13</sup>, Xin Yuan<sup>36</sup>, Jing Hua Zhao<sup>3</sup>, Eleftheria Zeggini<sup>2</sup>, David Schlessinger<sup>51</sup>, Manjinder Sandhu<sup>3,52</sup>, Dorret I Boomsma<sup>16</sup>, Manuela Uda<sup>15</sup>, Tim D. Spector<sup>9</sup>, Brenda WJH Penninx<sup>53-55</sup>, David Altshuler<sup>4,7</sup>, Peter Vollenweider<sup>56</sup>, Marjo Riitta Jarvelin<sup>17,26,42</sup>, Edward Lakatta<sup>51</sup>, Gerard Waeber<sup>56</sup>, Caroline S. Fox<sup>57,58</sup>, Leena Peltonen<sup>8,59,60</sup>, Leif C. Groop<sup>18</sup>, Vincent Mooser<sup>36</sup>, L. Adrienne Cupples<sup>11</sup>, Unnur Thorsteinsdottir<sup>10,61</sup>, Michael Boehnke<sup>12</sup>, Inês Barroso<sup>8</sup>, Cornelia Van Duijn<sup>13</sup>, Josée Dupuis<sup>11</sup>, Richard M. Watanabe<sup>23,62</sup>, Kari Stefansson<sup>10,61</sup>, Mark I. McCarthy<sup>1,2</sup>, Nicholas J. Wareham<sup>3</sup>, James B. Meigs<sup>5,63</sup>, Goncalo R. Abecasis<sup>12,†</sup>.

## **Six New Loci Associated with Body Mass Index Highlight a Neuronal Influence on Body Weight Regulation**

Cristen J. Willer<sup>1\*</sup>, Elizabeth K. Speliotes<sup>2,3\*</sup>, Ruth J.F. Loos<sup>4,5\*</sup>, Shengxu Li<sup>4,5\*</sup>, Cecilia M. Lindgren<sup>6</sup>, Iris M. Heid<sup>7</sup>, Sonja I. Berndt<sup>8</sup>, Amanda L. Elliott<sup>9,10</sup>, Anne U. Jackson<sup>1</sup>, Claudia Lamina<sup>7</sup>, Guillaume Lettre<sup>9,11</sup>, Noha Lim<sup>12</sup>, Helen N. Lyon<sup>3,11</sup>, Steven A. McCarroll<sup>9,10</sup>, Konstantinos Papadakis<sup>13</sup>, Lu Qi<sup>14,15</sup>, Joshua C. Randall<sup>6</sup>, Rosa Maria Roccasecca<sup>16</sup>, Serena Sanna<sup>17</sup>, Paul Scheet<sup>18</sup>, Michael N. Weedon<sup>19</sup>, Eleanor Wheeler<sup>16</sup>, Jing Hua Zhao<sup>4,5</sup>, Leonie C. Jacobs<sup>20</sup>, Inga Prokopenko<sup>6,21</sup>, Nicole Soranzo<sup>16,22</sup>, Toshiko Tanaka<sup>23</sup>, Nicholas J. Timpson<sup>24</sup>, Peter Almgren<sup>25</sup>, Amanda Bennett<sup>26</sup>, Richard N. Bergman<sup>27</sup>, Sheila A. Bingham<sup>28,29</sup>, Lori L. Bonnycastle<sup>30</sup>, Morris Brown<sup>31</sup>, Noël P. Burtt<sup>9</sup>, Peter Chines<sup>30</sup>, Lachlan Coin<sup>32</sup>, Francis S. Collins<sup>30</sup>, John M. Connell<sup>33</sup>, Cyrus Cooper<sup>34</sup>, George Davey Smith<sup>24</sup>, Elaine M. Dennison<sup>34</sup>, Parimal Deodhar<sup>30</sup>, Paul Elliott<sup>32</sup>, Michael R. Erdos<sup>30</sup>, Karol Estrada<sup>20</sup>, David M. Evans<sup>24</sup>, Lauren Gianniny<sup>9</sup>, Christian Gieger<sup>7</sup>, Christopher J. Gillson<sup>4,5</sup>, Candace Guiducci<sup>9</sup>, Rachel Hackett<sup>9</sup>, David Hadley<sup>13</sup>, Alistair S. Hall<sup>35</sup>, Aki S. Havulinna<sup>36</sup>, Johannes Hebebrand<sup>37</sup>, Albert Hofman<sup>38</sup>, Bo Isomaa<sup>39</sup>, Kevin B. Jacobs<sup>40</sup>, Toby Johnson<sup>41,42,43</sup>, Pekka Jousilahti<sup>36</sup>, Zorica Jovanovic<sup>5,44</sup>, Kay-Tee Khaw<sup>45</sup>, Peter Kraft<sup>46</sup>, Mikko Kuokkanen<sup>9,47</sup>, Johanna Kuusisto<sup>48</sup>, Jaana Laitinen<sup>49</sup>, Edward G. Lakatta<sup>50</sup>, Jian'an Luan<sup>4,5</sup>, Robert N. Luben<sup>45</sup>, Massimo Mangino<sup>51</sup>, Wendy L. McArdle<sup>52</sup>, Thomas Meitinger<sup>53,54</sup>, Antonella Mulas<sup>17</sup>, Patricia B. Munroe<sup>55</sup>, Narisu Narisu<sup>30</sup>, Andrew R. Ness<sup>56</sup>, Kate Northstone<sup>52</sup>, Stephen O'Rahilly<sup>5,44</sup>, Carolin Purmanns<sup>5,44</sup>, Matthew G. Rees<sup>30</sup>, Martin Ridderstråle<sup>57</sup>, Susan M. Ring<sup>52</sup>, Fernando Rivadeneira<sup>20,38</sup>, Aimo Ruokonen<sup>58</sup>, Manjinder S. Sandhu<sup>4,45</sup>, Jouko Saramies<sup>59</sup>, Laura J. Scott<sup>1</sup>, Angelo Scuteri<sup>60</sup>, Kaisa Silander<sup>47</sup>, Matthew A. Sims<sup>4,5</sup>, Kijoung Song<sup>12</sup>, Jonathan Stephens<sup>61</sup>, Suzanne Stevens<sup>51</sup>, Heather M. Stringham<sup>1</sup>, Y.C. Loraine Tung<sup>5,44</sup>, Timo T. Valle<sup>62</sup>, Cornelia M. Van Duijn<sup>38</sup>, Karani S. Vimalesarwan<sup>4,5</sup>, Peter Vollenweider<sup>63</sup>, Gerard Waeber<sup>63</sup>, Chris Wallace<sup>55</sup>, Richard M. Watanabe<sup>64</sup>, Dawn M. Waterworth<sup>12</sup>, Nicholas Watkins<sup>61</sup>, The Wellcome Trust Case Control Consortium<sup>65</sup>, Jacqueline C.M. Witteman<sup>38</sup>, Eleftheria Zeggini<sup>6</sup>, Guangju Zhai<sup>22</sup>, M. Carola Zillikens<sup>20</sup>, David Altshuler<sup>9,10</sup>, Mark J. Caulfield<sup>55</sup>, Stephen J. Chanock<sup>8</sup>, I. Sadaf Farooqi<sup>5,44</sup>, Luigi Ferrucci<sup>23</sup>, Jack M. Guralnik<sup>66</sup>, Andrew T. Hattersley<sup>67</sup>, Frank B. Hu<sup>14,15</sup>, Marjo-Riitta Jarvelin<sup>32</sup>, Markku Laakso<sup>48</sup>, Vincent Mooser<sup>12</sup>, Ken K. Ong<sup>4,5</sup>, Willem H. Ouwehand<sup>16,61</sup>, Veikko Salomaa<sup>36</sup>, Nilesh J. Samani<sup>51</sup>, Timothy D. Spector<sup>22</sup>, Tiinamaija Tuomi<sup>68,69</sup>, Jaakko Tuomilehto<sup>62</sup>, Manuela Uda<sup>17</sup>, André G. Uitterlinden<sup>20,38</sup>, Nicholas J. Wareham<sup>4,5</sup>, Panagiotis Deloukas<sup>16</sup>, Timothy M. Frayling<sup>19</sup>, Leif C. Groop<sup>25,70</sup>, Richard B. Hayes<sup>8</sup>, David J. Hunter<sup>9,14,15,46</sup>, Karen L. Mohlke<sup>71</sup>, Leena Peltonen<sup>9,16,72</sup>, David Schlessinger<sup>73</sup>, David P. Strachan<sup>13</sup>, H-Erich Wichmann<sup>7,74</sup>, Mark I. McCarthy<sup>6,21,75\*\*\*</sup>, Michael Boehnke<sup>1\*\*\*</sup>, Inês Barroso<sup>16\*\*\*</sup>, Gonçalo R. Abecasis<sup>18\*\*\*</sup>, Joel N. Hirschhorn<sup>3,11,76\*\*\*</sup>